

File No.:
ND/CT04/FF/2021/26720
dated 02.07.2021

Tele No.011-23236965
Fax.No.011-23236973

F. No. ND/CT/21/000044
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
New Drugs Division

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

To
Sun Pharmaceutical Industries Limited,
Acme Plaza, Andheri – Kurla Road,
Andheri (East), Mumbai,
Maharashtra – 400 059.

13 AUG 2021

Subject: Grant of permission to undertake Phase II/III Clinical Trial titled “A Phase 2/3, Multicenter, Randomized, Open-Label, Parallel-group Adaptive Clinical Trial to Evaluate the Efficacy and Safety of Tablets of Purified Aqueous Extract of Cocculus hirsutus in Treatment of Mild COVID-19 Disease”, Protocol No: ICR/21/007; Version No. 2.0 dated 17.07.2021 - regarding.

CT NOC No.: CT-ND/21/2021

Sir,

With reference to your application no. ND/CT/21/000044 dated 02.07.2021, please find enclosed herewith the permission in Form CT-06, No. **CT/ND/21/2021** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trials Rules, 2019 granted based on evaluation in consultation with Subject Expert Committee (SEC) as part of accelerated approval process in light of COVID-19 outbreak.

This permission is subject to the conditions, as mentioned below.

Yours faithfully,



(Dr. V. G. Somani)
Central Licensing Authority

Conditions of Permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol

from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by

Central Licensing Authority in accordance with the provisions of the said Chapter;

- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licensing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvi) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) **Investigational product should be manufactured in accordance with principles of GMP as per Indian GCP guidelines.**
- (xx) **The trial should be double blind clinical trial.**
- (xxi) **Accordingly, firm should submit the revised protocol to CDSCO.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits **Sun Pharmaceutical Industries Limited, Tandalja, Vadodara, Gujarat (India) – 390012** to conduct clinical trial of the **Investigational new drug** as per protocol No. **ICR/21/007; Version No. 2.0** dated **17.07.2021** in the below mentioned clinical trial sites

2. Details of new drug or investigational new drug:

Names of the new drug or investigational new drug:	Purified aqueous extract of <i>Cocculus hirsutus</i> tablets 300mg (Phytopharmaceutical drug)	
Therapeutic class:	Antiviral	
Dosage form:	Tablet	
Composition:	Each 300mg purified aqueous extract of <i>Cocculus hirsutus</i> film coated tablet contains: Magnoflorine NLT 0.1% w/w Sinococculine NLT 1.0% w/w 20-Hydroxyecdysone NLT 0.1% w/w Makisterone A NLT 0.05% w/w Excipients..... q.s. Colors..... Titanium Dioxide IP, Indigotindisulfonate Sodium USP-NF, Tartrazine Yellow, Ferric Oxide (Yellow) USP-NF	
Indications:	For treatment of mild COVID-19 disease	
Details of clinical trial sites-		
Sr. No.	Name of Principal Investigator & Trial sites	Ethics Committee Name/Registration Number
1.	Dr Khobragade Akash Ashok kumar St. George's Hospital, Mumbai, Maharashtra	Institutional Ethics Committee, GGMC, Mumbai, Maharashtra. ECR/382/Inst/MH/2013/RR-19
2	Dr. Pathak Niranjana Pandurang Department PCMC'S PGI Yashwantrao Chavan Memorial Hospital, Pune, Maharashtra.	Institutional Ethics Committee, Yashwantrao Chavan Memorial Hospital, Pune, Maharashtra. ECR/1236/Inst/MH/2019
3	Dr. Gofne Sandip Krishnrao Department of Medicine, District Civil Hospital, Aurangabad, Maharashtra.	Ethics Committee Ajanta Super speciality Hospital, Aurangabad, Maharashtra. ECR/1499/Inst/MH/2021
4	Dr. Parmar Kartikeya Ganpatlal B.J. Medical College and Civil Hospital, Ahmedabad, Gujarat.	Institutional Ethics Committee, B.J. Medical College and Civil Hos pital, Ahmedabad, Gujarat. ECR/72/Inst/GJ/2013/RR-19

5	Dr. Richa Giri GSVM Medical College, Kanpur, Uttar Pradesh.	Ethics Committee, GSVM Medical College, Kanpur, Uttar Pradesh. ECR/680/Inst/UP/2014/RR-20
6	Dr. Naganna Jilla Gandhi Hospital, Secunderabad, Telangana	Institutional Ethics Committee, Gandhi Medical College and Hospital, Secunderabad, Telangana. ECR/180/Inst/AP/2013/RR- 19
7	Dr. Chandrashekhar C. Mahakalkar Acharya Vinoba Bhave Rural Hospital, Wardha, Maharashtra.	Institutional Ethics Committee of DMIMS, Wardha, Maharashtra. ECR/440/Inst/MH/2013/RR-19
8	Dr. Uppe Abhay Gangadhar Dr. D.Y. Patil Hospital & Research Centre, Mumbai, Maharashtra.	Institutional Ethics Committee, D.Y. Patil Medical College, Navi Mumbai, Maharashtra. ECR/195/Inst/MH/2013/RR-19
9	Dr. Praveen Chabukswar (Consultant Pulmonologist) Ajanta Superspeciality Hospital, Aurangabad, Maharashtra.	Ethics Committee Ajanta Superspeciality Hospital, Aurangabad, Maharashtra. ECR/1499/Inst/MH/2021
10	Dr. Vaiyali Ramu Shanmuga Hospital, Salem, Tamil Nadu.	Shanmuga Medical Research Foundation Trust– Institutional Ethics Committee, Salem, Tamil Nadu. ECR/1046/Inst/TN/2018/RR-21
11	Dr. Soumik Chowdhury Health Point Hospital, Kolkata, West Bengal.	Health Point Ethics Committee, Kolkata, West Bengal. ECR/284/Inst/WB/2013/RR-19
12	Dr. Ambanna Gowda Citizen Hospital, Bangalore, Karnataka.	ACE Independent Ethics Committee, Bangalore, Karnataka. ECR/141/Indt/KA/2013/RR-19
13	Dr. Lokendra Gupta Medanta Hospital, Lucknow, Uttar Pradesh.	Institutional Ethics Committee Medanta, Lucknow, Uttar Pradesh. ECR/1529/INST/UP/2021
14	Dr. Mohd Sameer Beg Tender Palm Hospital, Lucknow, Uttar Pradesh.	Independent Ethics Committee Narayana Diagnostics, Lucknow, Uttar Pradesh. ECR/333/Indt/UP/2020

15	Dr. Ashish Kumar Asthma Bhawan, Jaipur, Rajasthan.	Institutional Ethics Committee Asthma Bhawan, Jaipur, Rajasthan. ECR/750/Inst/RJ/2015/RR-18
16	Dr. Pooja Khosla Sir Ganga Ram Hospital, New Delhi.	Sir Ganga Ram Hospital Ethics Committee, New Delhi. ECR/20/Inst/DL/2013/RR-19
17	Dr. Santosh S. Santosh Hospital, Bangalore, Karnataka.	Santosh Hospital, Institutional Ethics Committee, Bangalore, Karnataka. ECR/1062/Inst/KA/2018/RR-21

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

V. G. Somani

(Dr. V. G. Somani)

Central Licensing Authority
Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

New Delhi

Date:

13 AUG 2021

